Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A3 | Q9HAS3 | 3/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.51 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.51 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.51 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.51 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.51 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7184467 | 0.85 | SLC28A3 (0.51) | SLC28A3SLC5A1SLC5A2LGALS9LGALS1 | |
| SCHEMBL31619798 | 0.84 | TYR (0.52) | SLC28A3SLC5A1SLC5A2TYRKDM4E | |
| SCHEMBL6739168 | 0.84 | LGALS3 (0.51) | SLC28A3SLC5A1SLC5A2LGALS9LGALS1 | |
| SCHEMBL29278300 | 0.84 | LGALS3 (0.51) | SLC28A3SLC5A1SLC5A2LGALS9LGALS1 | |
| SCHEMBL30441333 | 0.84 | LGALS9 (0.48) | SLC28A3SLC5A1SLC5A2LGALS9LGALS1 | |
| SCHEMBL7193412 | 0.84 | MAOB (0.54) | SLC28A3SLC5A1SLC5A2HIF1AMAOB | |
| Hydrochloric Acid SCHEMBL28792398 | 0.83 | LGALS3 (0.50) | SLC28A3SLC5A1SLC5A2LGALS9LGALS1 | |
| SCHEMBL7193401 | 0.82 | TDP1 (0.57) | SLC28A3SLC5A1SLC5A2HIF1AMAOB | |
| SCHEMBL940121 | 0.82 | TDP1 (0.57) | SLC28A3SLC5A1SLC5A2HIF1AMAOB | |
| SCHEMBL8762538 | 0.82 | LGALS9 (0.60) | SLC28A3LGALS9LGALS1LGALS3LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004753-B2 | Methods for treating tauopathy | THE J. DAVID GLADSTONE INSTITUTES (US) | 2018-06-26 | — | — | US | disclosed |
| US-10004753-B2 | Methods for treating tauopathy | THE J. DAVID GLADSTONE INSTITUTES (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170368080-A1 | METHODS FOR TREATING TAUOPATHY | THE J. DAVID GLADSTONE INSTITUTES | 2017-12-28 | — | — | US | disclosed |
| US-20170368080-A1 | METHODS FOR TREATING TAUOPATHY | THE J. DAVID GLADSTONE INSTITUTES | 2017-12-28 | — | — | US | disclosed |
| EP-3244914-A1 | METHODS FOR TREATING TAUOPATHY | The J. David Gladstone Institutes (US) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016115520-A1 | METHODS FOR TREATING TAUOPATHY | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-07-21 | — | — | WO | disclosed |
| EP-1602354-B1 | Use of polyglutamic acid or its salts | MEIJI SEIKA KAISHA (JP) | 2008-11-05 | — | — | EP | disclosed |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1602354-A1 | HAIR TREATMENT COMPOSITION AND HAIR COSMETIC FOR DAMAGED HAIR | Meiji Seika Kaisha, Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004753-B2 | Methods for treating tauopathy | MAPT, PYGB, CHAT | SLC28A3 610/4885SLC5A1 645/4885SLC5A2 923/4885 |
| US-20060165636-A1 | Hair treatment composition and hair cosmetic for damaged hair | CUTA, COL14A1, PRKDC | SLC28A3 2901/4885SLC5A1 3272/4885SLC5A2 3680/4885 |
| US-20170368080-A1 | METHODS FOR TREATING TAUOPATHY | MAPT, PYGB, CHAT | SLC28A3 610/4885SLC5A1 645/4885SLC5A2 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.